Pacific Biosciences of California Inc. (PACB)

2.45
0.03 1.20
NASDAQ : Health Technology
Prev Close 2.48
Open 2.51
Day Low/High 2.41 / 2.55
52 Wk Low/High 2.21 / 5.70
Volume 374.82K
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 116.25M
Market Cap 298.76M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

SMRT Sequencing Of Human Genomes To Be Showcased At AGBT Conference

SMRT Sequencing Of Human Genomes To Be Showcased At AGBT Conference

Presentations will highlight importance of SMRT Sequencing for rare diseases, structural variation, and more

Pacific Biosciences Announces Fourth Quarter And Annual 2017 Financial Results

Pacific Biosciences Announces Fourth Quarter And Annual 2017 Financial Results

Annual Product and Service Revenue Increases 19% Year over Year

Commit To Purchase Pacific Biosciences of California At $2.50, Earn 24.4% Annualized Using Options

Investors eyeing a purchase of Pacific Biosciences of California Inc stock, but cautious about paying the going market price of $3.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 40 cents.

PacBio And GENEWIZ Announce Winner Of The 2017 AACR SMRT Grant

PacBio And GENEWIZ Announce Winner Of The 2017 AACR SMRT Grant

Will Receive Iso-Seq RNA Sequencing on the PacBio Sequel System and Bioinformatics Support

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.

Pacific Biosciences Of California, Inc. Announces Third Quarter 2017 Financial Results

Pacific Biosciences Of California, Inc. Announces Third Quarter 2017 Financial Results

Product and Service Revenue Increases by 9% Over Same Period in Previous Year

Pacific Biosciences of California Becomes Oversold (PACB)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Recent Projects Highlight Success Of SMRT Sequencing For Characterizing Structural Variation In Human Genomes

Recent Projects Highlight Success Of SMRT Sequencing For Characterizing Structural Variation In Human Genomes

PacBio Sequencing Reveals More Functionally Important Variants; Complete Solution for Structural Variant Detection to be Featured at ASHG Annual Meeting

Structural Variation Detection A Key Focus Of PacBio Sequencing Projects Presented At ASHG Annual Meeting

Structural Variation Detection A Key Focus Of PacBio Sequencing Projects Presented At ASHG Annual Meeting

More than 30 presentations demonstrate utility of SMRT Sequencing for human biomedical applications

Commit To Buy Pacific Biosciences of California At $5, Earn 34.4% Annualized Using Options

Investors considering a purchase of Pacific Biosciences of California Inc shares, but cautious about paying the going market price of $5.10/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2018 put at the $5 strike, which has a bid at the time of this writing of 90 cents.

Pacific Biosciences Of California, Inc. Announces Second Quarter 2017 Financial Results

Pacific Biosciences Of California, Inc. Announces Second Quarter 2017 Financial Results

Product and Service Revenue Increases by 17% Over Same Period in Previous Year

PacBio Announces New Agreement With Novogene To Purchase Ten Sequel Systems

PacBio Announces New Agreement With Novogene To Purchase Ten Sequel Systems

Increases Novogene's Capacity to Run 20 Sequel Systems at a Time

PacBio Technology Resolves Complex Maize Genome, Driving Demand For Other Large-Scale AgBio Sequencing Projects

SMRT Sequencing Offers Significant Improvements for Reference Genomes at Much Lower Cost

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering

Pacific Biosciences of California, AveXis and Novavax were among the biotech stock movers in premarket trading on Thursday.

Recent Publications Demonstrate Rapid Adoption Of SMRT Sequencing For Plant And Animal Transcriptome Analysis

Long Reads Reveal Important Genes and Splicing Complexity Missed by Short-Read Sequencers

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Pacific Biosciences of California, Alexion Pharmaceuticals and Arena Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Pacific Biosciences Of California, Inc. Announces First Quarter 2017 Financial Results

Product and Service Revenue Increases by 60% Over Same Period in Previous Year

TheStreet Quant Rating: D- (Sell)